Arbutus Biopharma Corporation (ABUS) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Arbutus Biopharma Corporation (ABUS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $848.8M, listed on NASDAQ, employing roughly 44 people, carrying a beta of 0.62 to the broader market. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Led by Lindsay Androski, public since 2007-07-26.
Snapshot as of May 15, 2026.
- Spot Price
- $4.25
- Total OI
- 17.3K